Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and SBRT in Early Stage NSCLC
NCT03050554Phase 2Terminated
- Sponsor
- Toragen, Inc.
- Start
- Oct 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in non-small cell lung cancer (NSCLC), sponsored by Toragen, Inc.. Started Oct 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03050554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050554.